We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 PR Newswire CAMBRIDGE...
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 PR Newswire CAMBRIDGE, Mass., March 5, 2024...
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass., Feb. 27, 2024...
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 PR Newswire CAMBRIDGE, Mass., Feb. 27, 2024 CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL...
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors PR Newswire CAMBRIDGE, Mass., Feb. 12, 2024 Alignment with US Food...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 3.8 | 6.02600697748 | 63.06 | 68.72 | 61.795 | 595389 | 64.88359688 | CS |
4 | -10.28 | -13.326419497 | 77.14 | 77.87 | 61.795 | 654710 | 67.63647001 | CS |
12 | -9.73 | -12.7040083562 | 76.59 | 89.39 | 61.795 | 497259 | 75.97150579 | CS |
26 | 13.86 | 26.1509433962 | 53 | 89.39 | 49.02 | 481504 | 71.84630582 | CS |
52 | 31.48 | 88.9768230639 | 35.38 | 89.39 | 33.03 | 476417 | 60.17105565 | CS |
156 | 48.76 | 269.392265193 | 18.1 | 89.39 | 7.09 | 306155 | 44.51414434 | CS |
260 | 48.76 | 269.392265193 | 18.1 | 89.39 | 7.09 | 306155 | 44.51414434 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions